Intra-Cellular Therapies Balance Sheet Health
Financial Health criteria checks 5/6
Intra-Cellular Therapies has a total shareholder equity of $1.1B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.3B and $179.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.01b |
| Equity | US$1.14b |
| Total liabilities | US$179.62m |
| Total assets | US$1.32b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 23I's short term assets ($1.3B) exceed its short term liabilities ($166.1M).
Long Term Liabilities: 23I's short term assets ($1.3B) exceed its long term liabilities ($13.5M).
Debt to Equity History and Analysis
Debt Level: 23I is debt free.
Reducing Debt: 23I had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 23I has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 23I has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.